|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the International Metastatic Renal Cell Carcinoma Database Consortium (imdc) dataset, a retrospective analysis of patients with metastatic renal cell carcinoma (mrcc) treated with nivolumab or cabozantinib in the second line after prior therapy targeted to the vascular endothelial growth factor receptor (vegfr) was performed.
|
31043824 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a multicenter phase 2 study, performed in patients with mRCC not amenable to or progressive on a vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor (TKI) containing treatment regimen, we assessed whether the addition of this metronomic dosing schedule of cyclophosphamide to therapy with everolimus could result in an improvement of progression-free survival (PFS) after 4 months of treatment.
|
30756132 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since continuing blockade of VEGF may be of value, we studied the combination of bevacizumab with temsirolimus in mRCC patients relapsing after first-line treatment.
|
30374686 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adult patients with mRCC were eligible for everolimus treatment after first-line vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors or bevacizumab therapy.
|
30661070 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors.
|
31264522 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Over the past 2 decades, several vascular endothelial growth factor (VEGF) and tyrosine kinase inhibitors have been the mainstay for first- and second-line treatment of mRCC.
|
30858035 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We reviewed the clinical efficacy of axitinib after nivolumab treatment failure in six patients with metastatic renal cell carcinoma (RCC); the patients had received nivolumab treatment following vascular endothelial growth factor receptor (VEGFR) inhibitors.
|
30924496 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In metastatic colorectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC), vascular endothelial growth factor inhibitor (VEGF-i) therapy is commonly used to improve overall survival.
|
30459123 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks.
|
29956884 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
|
28963640 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitors are widely used in treatment of metastatic renal cell carcinoma.
|
30058939 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, 1992 eligible patients initiated 1 L treatment for mRCC from 2011 through 2015: 1752 (88%) received TK/VEGF-directed agents and 233 (12%) received mTOR-directed agents; 1674 (84%) received oral treatments, and 318 (16%) received IV treatments.
|
31174493 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) and those who are treatment naive, respectively.
|
31501271 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatotoxicity is a well-known adverse effect of vascular endothelial growth factor receptor (VEGFR) tyrosine-kinase inhibitors (TKIs), usually employed for the treatment of metastatic renal cell carcinoma (mRCC).
|
31764847 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine the prognostic factors of progression-free survival (PFS) and overall survival (OS) in non-nephrectomized patients with synchronous metastatic renal cell carcinoma (mRCC) receiving first-line vascular endothelial growth factor (VEGF)-targeted therapy or immunotherapy.
|
30785902 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PD-1 inhibitor nivolumab improved the OS rate of patients with mRCC following VEGF inhibitors.
|
30722031 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase 2 study (FavorAx), we assessed the activity of axitinib in mRCC patients with a favorable risk and history of prior vascular endothelial growth factor receptor (VEGFR)-directed therapy.
|
30607698 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Major strides have been made in the management of metastatic renal cell carcinoma by targeting the vascular endothelial growth factor (VEGF) pathway.
|
30886831 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individualised sunitinib therapy is feasible, safe and an effective method to manage toxicity with one of the best efficacy seen for oral vascular endothelial growth factor inhibitors in metastatic renal cell carcinoma.CLINICALTRIALS.
|
30648632 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and toxicity data for vascular endothelial growth factor inhibitor therapies in CUP-mRCC patients are few.
|
30268423 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with mRCC prescribed everolimus after failure of vascular endothelial growth factor-tyrosine kinase inhibitor were enrolled.
|
31262924 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
|
30682039 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI).
|
29027615 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) inhibitors have been successfully used to treat metastatic renal cell carcinoma (mRCC); however, resistance eventually develops in most cases.
|
31171735 |
2019 |
|
Metastatic Renal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In metastatic renal-cell carcinoma (mRCC), recent data have shown efficacy of first-line ipilimumab and nivolumab (ipi-nivo) as well as immuno-oncology (IO)/vascular endothelial growth factor (VEGF) inhibitor combinations.
|
31445844 |
2019 |